Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

BACKGROUND: The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell transplant, we investigated the in vitro activity of daratumumab on mobilized...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Exp Hematol Oncol
Egile Nagusiak: Ma, Xun, Wong, Sandy W., Zhou, Ping, Chaulagain, Chakra P., Doshi, Parul, Klein, Andreas K., Sprague, Kellie, Kugelmass, Adin, Toskic, Denis, Warner, Melissa, Miller, Kenneth B., Lee, Lisa, Varga, Cindy, Comenzo, Raymond L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192105/
https://ncbi.nlm.nih.gov/pubmed/30356940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0119-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak